Similar articles

• Carbocysteine.

  Brown DT. Brown DT. Drug Intell Clin Pharm. 1988 Jul-Aug;22(7-8):603-8. doi: 10.1177/106002808802200721. Drug Intell Clin Pharm. 1988. PMID: 3046890 Review.
• Evaluation of the activity of the carbocysteine-sobrerol combination on mucus spinnability.

  Distefano SM, Palermo F, Crimi N, Mistretta A, Pamparana F, Messa A. Distefano SM, et al. Int J Clin Pharmacol Res. 1988;8(1):31-5. Int J Clin Pharmacol Res. 1988. PMID: 3284830 Clinical Trial.
• [Mucolytic therapy for respiratory system diseases. Clinical-experimental results before and after treatment with Transbronchin].

  Primer G. Primer G. Ther Ggw. 1975 Aug;114(8):1251-66. Ther Ggw. 1975. PMID: 1108276 Clinical Trial. German. No abstract available.
• [Changes in IgA levels in nasal mucus after upper respiratory tract diseases in infants treated with carbocysteine].

  Henocq A, Moreau C, Mallet E, Sauger F, de Menibus CH. Henocq A, et al. Ann Otolaryngol Chir Cervicofac. 1985;102(5):373-5. Ann Otolaryngol Chir Cervicofac. 1985. PMID: 4037622 French.
• S-carboxymethyl-L-cysteine.

  Mitchell SC, Steventon GB. Mitchell SC, et al. Drug Metab Rev. 2012 May;44(2):129-47. doi: 10.3109/03602532.2011.631015. Drug Metab Rev. 2012. PMID: 22497630 Review.